DocumentRX-9728
Issued
Read4 min

MHRA Launches AdvanceGxP as EMA Clarifies Equivalence Testing

MHRA launches AdvanceGxP with Office for Life Sciences funding; EMA adds 13 Q&As on quality-attribute comparison; MHRA's women's health strategy follows analysis of 4,616 trial applications.

TAG K-5151 · 869 words on the filing

Euro Roundup: UK MHRA launches service to support early consideration of good practices - RAPS
Euro Roundup: UK MHRA launches service to support early consideration of good practices - RAPSAI-generated

Summary of findings

  • MHRA's AdvanceGxP service, funded by the Office for Life Sciences, will be free during pilot phases; applications not yet open.
  • EMA added 13 questions on comparing quality attributes to its Q&A, building on a July 2021 reflection paper.
  • MHRA found pregnant women in 1.1% of 4,616 UK trial applications (2019-2023); breastfeeding women in 0.6%.
  • MHRA opens registration in late November for its AI tool that screens draft trial protocols.
  • EMA set three AI principles for staff: human oversight, human-led decision-making, ethical use.

The UK MHRA has launched AdvanceGxP, a free-to-access service designed to help companies developing emerging medicines technologies consider good practice (GxP) requirements earlier in development — before key decisions on facilities, processes and validation get locked in.

The agency secured funding from the Office for Life Sciences to develop and test the service, which will initially focus on advanced manufacturing technologies. MHRA's reasoning is straightforward. Innovation in medicines and manufacturing is moving fast, and there is often limited precedent, guidance or case study material showing how GxP principles apply. That gap creates uncertainty exactly when companies are committing capital.

What does AdvanceGxP actually do?

The service gives organizations developing novel and potentially disruptive medicines technologies earlier access to practical, regulator-led GxP expertise. MHRA wants compliance considered before development decisions are fixed, reducing the risk of redesign and delays and supporting more sustainable approaches.

The funding will pay for a specialist team. The roadmap covers how organizations access the service, which technologies and projects get priority, and how it connects with existing MHRA support.

MHRA was explicit about the limits: "AdvanceGxP will complement existing MHRA services and formal inspection," the agency said. "It will not be an inspection or pre-inspection clearance, prescribe a particular technical solution, or guarantee a future regulatory or inspection outcome."

Applications aren't open yet. Capacity will be limited during development and testing, and the service will be free through the pilot phases. Early projects will inform future charging arrangements and how MHRA can run the service sustainably.

Companies can register interest now. MHRA wants details from organizations working on novel or disruptive medicines technologies, AI applications, or sustainability elements in chemistry, manufacture and controls (CMC).

How should companies compare quality attributes?

EMA has added 13 questions on comparing quality attributes to demonstrate therapeutic equivalence, updating Part 2 of its quality Q&A document. The new section builds on a July 2021 reflection paper that set out a statistical methodology for comparative assessment of quality attributes in drug development.

The reflection paper lacked guidance on conducting and describing in vitro comparisons. The Q&A now fills that gap with a 10-part framework covering every step — from defining critical quality attributes that may affect safety and efficacy to producing the final report.

Key points for regulatory teams:

  • EMA encourages companies to choose similarity conditions based on the potential relationship between quality attributes and a product's safety and efficacy.
  • The guidance includes two worked examples of similarity approaches.
  • Between-batch variability within the test or reference population must be thoroughly investigated.
  • Where companies find no statistical between-batch variability, EMA supports pooling results from batches of the same population — but cautions that ruling out between-batch variability may be difficult, especially in small datasets.

What is MHRA doing on women's health?

Weeks after EMA set priorities for better representation of women in drug development, MHRA unveiled its own strategy for tackling women's health evidence gaps. The numbers behind it are stark. MHRA analyzed 4,616 UK clinical trial applications submitted between 2019 and 2023 and found pregnant women represented in just 1.1% of studies and breastfeeding women in 0.6%. Women of childbearing potential appeared in 33% of trials.

The program runs on four strategic themes. One covers using data to improve health outcomes for women, with real-world data and advanced analytical methods to identify sex-based differences. MHRA sees emerging modeling techniques and synthetic data as resources for spotting outcome differences in data-poor contexts. Another theme targets innovation and quality in healthcare products for women, using existing regulatory pathways to close gaps — including defining how its frameworks can stimulate product development and evidence generation. The overall aim: ensure differences in safety and effectiveness between men and women are identified and addressed.

What are the AI developments?

Two separate AI moves landed. EMA released principles and rules for staff use of artificial intelligence, following the March 2024 launch of its Scientific Explorer knowledge-mining tool and the rollout of Microsoft Copilot 365. The agency runs two versions of Microsoft's tool — Copilot chat and Copilot 365 — for productivity.

The three principles: human oversight, human-led decision-making, and ethical use. Rules include knowing when, and when not, to use AI. Staff can use it to summarize and analyze information, provided it is not restricted, private or confidential. EMA is also preparing AI Act-aligned guidance on generating and modifying content — written material, speeches, presentations, images, audio and video, covering both external and internal use.

MHRA, meanwhile, built an AI tool for spotting potential issues in draft clinical trial protocols. Sponsors and their representatives will use it pre-submission to catch problems that could trigger requests for more information. The tool assesses whether MHRA is likely to require clarification on emergency unblinding, clinical eligibility criteria, contraceptive requirements, and adverse event recording and reporting. Registration opens in late November, with phased onboarding of sponsors.

Finally, EFPIA backed an IFPMA statement on implementing a global chemicals framework, calling for science-based, risk-proportionate implementation that considers hazard, exposure and conditions of use.

The through-line this week: both agencies are pushing regulatory engagement and tooling upstream, before the filing lands.

via Regulatory Focus (Google News) (Source)

Share this article:

More from Daniel Okafor

Daniel Okafor

Show full bio

Correspondent covering technology and product news in global pharmaceutical industry at PharmInsider.

11 articles

Linked filings

  1. V-9816
  2. P-4283
  3. E-9238
  4. T-7393
  5. K-6477

« Previous filingNext filing »